Skip to main content
رجوع
Watch Compare

Xenetic Biosciences, Inc.

جودة البيانات: 100%
XBIO
Nasdaq Manufacturing Chemicals
KWD 3.06
▼ KWD 0.09 (-2.86%)
القيمة السوقية: 7.22 M
السعر
KWD 3.15
القيمة السوقية
7.22 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Revenue grew 26.54% annually over 5 years — strong growth
Negative free cash flow of -2.29 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.50%

النمو

Revenue Growth (5Y)
26.54%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)19.04%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-63.78%
أقل من متوسط القطاع (-53.41%)
ROIC-53.28%
Net Margin-90.07%
Op. Margin-95.23%

الأمان

Debt / Equity
N/A
Current Ratio4.56
Interest Coverage-19.15

التقييم

PE (TTM)
-2.69
أقل من متوسط القطاع (-1.48)
P/B Ratio1.82
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -2.7 -1.5
P/B 1.8 1.6
ROE % -63.8 -53.4
Net Margin % -90.1 -41.5
Rev Growth 5Y % 26.5 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 19.04% Revenue Growth (3Y) 8.25%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 26.54% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.98 M Net Income (TTM) -2.68 M
ROE -63.78% ROA -51.45%
Gross Margin N/A Operating Margin -95.23%
Net Margin -90.07% Free Cash Flow (TTM) -2.29 M
ROIC -53.28% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4.56
Interest Coverage -19.15 Asset Turnover 0.57
Working Capital 3.96 M Tangible Book Value 3.96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.69 Forward P/E N/A
P/B Ratio 1.82 P/S Ratio 2.42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -31.68%
Market Cap 7.22 M Enterprise Value 7.22 M
Per Share
EPS (Diluted TTM) -1.58 Revenue / Share 1.30
FCF / Share -1.00 OCF / Share -1.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85.30%
SBC-Adj. FCF -2.36 M Growth Momentum -7.50

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.98 M 2.50 M 2.54 M 1.71 M 1.16 M
Net Income -2.68 M -3.96 M -4.13 M -6.55 M -5.65 M
EPS (Diluted) -1.58 -2.57 -2.71 -0.46 —
Gross Profit — — — — —
Operating Income -2.83 M -4.20 M -4.52 M -6.72 M -5.75 M
EBITDA — — — — —
R&D Expenses 3.07 M 3.29 M 3.49 M 4.77 M 3.16 M
SG&A Expenses — — — — —
D&A — — — 0.0 0.0
Interest Expense 147,997.0 249,861.0 355,757.0 167,152.0 100,467.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8.36 M 6.90 M 10.61 M 14.72 M 19.82 M
Total Liabilities 968,025.0 894,263.0 809,585.0 1.07 M 1.42 M
Shareholders' Equity 7.40 M 6.01 M 9.80 M 13.65 M 18.39 M
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 8.05 M 6.59 M 9.59 M 13.65 M 18.72 M
Current Liabilities 968,025.0 894,263.0 809,585.0 1.07 M 1.42 M